An End-to-End Platform for Single Cell Analysis
Powered by Robotics & AI
The future of neurodegenerative medicine is at our fingertips.
Valted Seq has created the largest homogenous single cell database of brain samples to empower biomarker and therapeutic target discovery spearheaded by world-renowned scientists Dr. Ted Dawson and Dr. Valina Dawson of Johns Hopkins University.
We believe that a deeper understanding of neurodegenerative pathways at the cellular level is essential to develop precision therapeutics and identify novel biomarkers for some of the most challenging neurodegenerative diseases, including Alzheimer’s and Parkinson’s.
Valted Seq is part of the D&D Pharmatech/Neuraly family of companies, which works hand in hand with leading medical research institutions to advance groundbreaking healthcare innovations.
“We expect this unprecedented repository of single-cell genomics, which Valted Seq will explore using advanced big data analytics, will accelerate progress towards better outcomes for patients.”
— Dr. Valina Dawson | Co-founder, Valted Seq
Apr. 7, 2025
Valted Seq Launches Revolutionary AI-Powered Genomics Tool to Accelerate Breakthroughs in Healthcare and Life Sciences.
Read Article
April 21, 2021
Valted Seq Announces Exclusive Right to Develop PAR and c-Abl Pathway Biomarker Assays for Diagnosis of Neurodegenerative Diseases
Read Article
Sept. 11, 2020
Newly Launched Valted Seq Working to Discover Disease Pathways, Biomarkers
Read Article
Sept. 9, 2020
D&D Pharmatech Announces Launch of Valted Seq Subsidiary Focusing on Discovery of Neurodegenerative Disease Pathways and Biomarkers
Read Article
Contact Us
Address
704 Quince Orchard Rd, Suite 320
Gaithersburg, MD 20878
Email
info@valtedseq.com